Pacritinib’s Lack of Myelosuppression May Be Due to Lack of JAK1, IRAK1 Inhibition
Profile of pacritinib suggests potential role in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
ASH 2014
Proposed Prognostic Model for CNS Risk in Aggressive B-Cell Lymphoma Validated
Investigators validated the German High-Grade Non-Hodgkin Lymphoma Study Group’s new prognostic model for aggressive B-cell lymphoma.
R-CHOP Alone Induces High Complete Response in Non-Bulky Large B Cell Lymphoma
Addition of radiotherapy should be reserved for the minority of patients with non-bulky limited-stage diffuse large B cell lymphoma (DLBCL).
Pomalidomide, Bortezomib, Dexamethasone Highly Effective in Lenalidomide-Refractory Multiple Myeloma
Pomalidomide, bortezomib, and dexamethasone is a highly effective combination in multiple myeloma refractory to lenalidomide.
CTL019 Cells Demonstrate Strong Response in Pediatric Patients with Acute Lymphocytic Leukemia
CTL019 cells cause strong, durable responses in pediatric patients with relapsed, refractory acute lymphocytic leukemia (ALL).
Blinatumumab May Be Effective for B-Precursor Acute Lymphocytic Leukemia (ALL)
Blinatumomab resulted in complete minimal residual disease (MRD) in 78% of patients with acute lymphocytic leukemia (ALL).
Clinical Benefit Observed with Pembrolizumab in Heavily Pretreated Classical Hodgkin Lymphoma
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Nivolumab Highly Effective in Relapsed/Refractory Classical Hodgkin Lymphoma
Nivolumab-mediated programmed cell death-1 (PD-1) blockade produced responses in classical Hodgkin lymphoma (cHL).
Pacritinib Suppresses Leukemic Outgrowth in FLT3-ITD-Driven Acute Myeloid Leukemia (AML)
Pacritinib suppresses leukemic outgrowth from stroma-adherent cells in FLT3-ITD-driven acute myeloid leukemia (AML).
Lenalidomide, Doxorubicin, Dexamethasone (RAD) Induction Triplet Effective in Multiple Myeloma
Induction with the lenalidomide, doxorubicin, dexamethasone (RAD) triplet is effective in newly diagnosed multiple myeloma.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASH 2014
